

# Paula ZarÄ~ba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4807365/publications.pdf>

Version: 2024-02-01

26  
papers

447  
citations

759233

12  
h-index

713466

21  
g-index

27  
all docs

27  
docs citations

27  
times ranked

675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT 6 receptor antagonists. Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 63-81.	5.5	72
2	Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression. <i>Pharmacological Reports</i> , 2015, 67, 465-472.	3.3	55
3	Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1195-1214.	3.5	44
4	New investigational drugs for the treatment of neuropathic pain. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1093-1104.	4.1	37
5	The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice. <i>Pharmacological Reports</i> , 2015, 67, 1155-1162.	3.3	37
6	Search for new multi-target compounds against Alzheimer's disease among histamine H3 receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2020, 185, 111785.	5.5	27
7	Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors—Molecular docking and pharmacodynamic studies. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 362-372.	4.0	19
8	Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 256-273.	5.5	17
9	Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112743.	5.5	17
10	Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. <i>European Journal of Pharmacology</i> , 2016, 776, 146-155.	3.5	15
11	2-Substituted 4-hydroxybutanamides as potential inhibitors of $\hat{1}^3$ -aminobutyric acid transporters mGAT1 and mGAT4: Synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5154-5167.	3.0	14
12	Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives. <i>Bioorganic Chemistry</i> , 2019, 90, 103084.	4.1	13
13	$\hat{1}^{\pm}$ -Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2104-2111.	3.0	11
14	Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice. <i>European Journal of Medicinal Chemistry</i> , 2020, 188, 111920.	5.5	11
15	Multidirectional <i>in vitro</i> and <i>in cellulo</i> studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer's disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1944-1952.	5.2	9
16	Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2021, 114, 105129.	4.1	8
17	Metabolic benefits of 1-(3-(4-( <i>o</i> -tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective $\hat{1}^{\pm}$ -adrenoceptor antagonist. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 609-619.	3.3	7
18	Docking and pharmacodynamic studies on hGAT1 inhibition activity in the presence of selected neuronal and astrocytic inhibitors. Part I. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 85, 171-181.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity. ACS Chemical Neuroscience, 2021, 12, 3073-3100.	3.5	6
20	Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity. European Journal of Medicinal Chemistry, 2021, 221, 113512.	5.5	6
21	Progress in the Search for New Dopamine Transporter Inhibitors. Current Medicinal Chemistry, 2015, 22, 3255-3277.	2.4	5
22	Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors. Current Medicinal Chemistry, 2021, 28, 750-776.	2.4	4
23	Antiarrhythmic and $\alpha$ -Adrenoceptor Antagonistic Properties of Novel Arylpiperazine Derivatives of Pyrrolidin-2-one. Archiv Der Pharmazie, 2015, 348, 861-867.	4.1	3
24	Biphenylalkoxyamine Derivatives as Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. Molecules, 2021, 26, 3580.	3.8	3
25	The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia. Pharmaceuticals, 2021, 14, 1065.	3.8	1
26	Novel gamma-aminobutyric acid reuptake inhibitor improves spatial learning and memory in Morris water maze and radial arm water maze tests. Pharmacological Reports, 2015, 67, 13.	3.3	0